Telacebec (Q203), a New Antituberculosis Agent

N Engl J Med. 2020 Mar 26;382(13):1280-1281. doi: 10.1056/NEJMc1913327.

Authors

Affiliations

¹ TASK Applied Science, Cape Town, South Africa dr.veronique@task.org.za.
² University of Cape Town Lung Institute, Cape Town, South Africa.
³ Qurient, Seongnam, South Korea.
⁴ TASK Laboratory, Cape Town, South Africa.
⁵ TASK Applied Science, Cape Town, South Africa.
⁶ Stellenbosch University, Cape Town, South Africa.

PMID: 32212527
DOI: 10.1056/NEJMc1913327

No abstract available

Publication types

Clinical Trial, Phase II
Letter
Randomized Controlled Trial

MeSH terms

Administration, Oral
Antitubercular Agents / administration & dosage*
Antitubercular Agents / adverse effects
Dose-Response Relationship, Drug
Drug Therapy, Combination
Ethambutol / administration & dosage
Humans
Imidazoles / administration & dosage*
Imidazoles / adverse effects
Isoniazid / administration & dosage
Mycobacterium tuberculosis / drug effects*
Piperidines / administration & dosage*
Piperidines / adverse effects
Pyrazinamide / administration & dosage
Pyridines / administration & dosage*
Pyridines / adverse effects
Rifampin / administration & dosage
Tuberculosis, Pulmonary / drug therapy*

Substances

Antitubercular Agents
Imidazoles
Piperidines
Pyridines
Pyrazinamide
telacebec
Ethambutol
Isoniazid
Rifampin